Fibrosis, characterized by uncontrolled extracellular matrix deposition, is a common phenomenon seen in different organs and tissues, bringing about disastrous influence on the function. Fibrosis can be induced by aging and diseases, such as sarcopenia during aging, renal fibrosis following diabetes, liver fibrosis following non-alcohol fatty liver disease; can be elicited by trauma or surgery, such as shoulder stiffness and elbow stiffness; and can also be a feature of the tumor, in which is also known as epithelial-mesenchymal transition. Currently, anti-fibrosis therapies are investigated broadly, while the complexity of this condition retards the development of effect modalities remarkably. Therefore, a better understanding of the mechanisms of fibrosis-related disorders is of urgent need.
Recent decades have witnessed remarkable advancement in multi-omic investigations and the progress of pharmacogenomics. Countless potential targets are unveiled by integrating the data of genomics and pharmacology. Since fibrosis and related disorders have various manifestations at the cellular level, proteomic level, and transcriptional level, integrative analysis is of vital importance in identifying targets. Moreover, the interplay between different cells in fibrotic tissue is also finely described by single-cell sequencing and spatial-transcriptome, et al, greatly broadening the understanding of the progress of fibrosis. Therefore, this research topic aims to study the underlying mechanisms of fibrosis and related diseases with specific attention to molecular targets. We welcome research revealing the mechanisms of fibrosis and studies to identify novel molecules against fibrogenesis.
In this Research Topic, we welcome original papers, reviews, letters, and systematic reviews, including but not limited to:
• Mechanisms and targets identification of fibrosis and related disorders;
• Discovery of novel targets with anti-fibrotic potential;
• Translational research of novel targets to regulate fibrogenesis in disorders;
Pure in silico approaches in manuscripts suggesting modes of action of compounds without experimental validation and manuscripts that report effects of chemically undefined compounds (e.g. plant extracts) are generally not considered.
Fibrosis, characterized by uncontrolled extracellular matrix deposition, is a common phenomenon seen in different organs and tissues, bringing about disastrous influence on the function. Fibrosis can be induced by aging and diseases, such as sarcopenia during aging, renal fibrosis following diabetes, liver fibrosis following non-alcohol fatty liver disease; can be elicited by trauma or surgery, such as shoulder stiffness and elbow stiffness; and can also be a feature of the tumor, in which is also known as epithelial-mesenchymal transition. Currently, anti-fibrosis therapies are investigated broadly, while the complexity of this condition retards the development of effect modalities remarkably. Therefore, a better understanding of the mechanisms of fibrosis-related disorders is of urgent need.
Recent decades have witnessed remarkable advancement in multi-omic investigations and the progress of pharmacogenomics. Countless potential targets are unveiled by integrating the data of genomics and pharmacology. Since fibrosis and related disorders have various manifestations at the cellular level, proteomic level, and transcriptional level, integrative analysis is of vital importance in identifying targets. Moreover, the interplay between different cells in fibrotic tissue is also finely described by single-cell sequencing and spatial-transcriptome, et al, greatly broadening the understanding of the progress of fibrosis. Therefore, this research topic aims to study the underlying mechanisms of fibrosis and related diseases with specific attention to molecular targets. We welcome research revealing the mechanisms of fibrosis and studies to identify novel molecules against fibrogenesis.
In this Research Topic, we welcome original papers, reviews, letters, and systematic reviews, including but not limited to:
• Mechanisms and targets identification of fibrosis and related disorders;
• Discovery of novel targets with anti-fibrotic potential;
• Translational research of novel targets to regulate fibrogenesis in disorders;
Pure in silico approaches in manuscripts suggesting modes of action of compounds without experimental validation and manuscripts that report effects of chemically undefined compounds (e.g. plant extracts) are generally not considered.